|
1
|
Masliah-Planchon J, Pasmant E, Luscan A,
Laurendeau I, Ortonne N, Hivelin M, Varin J, Valeyrie-Allanore L,
Dumaine V, Lantieri L, et al: MicroRNAome profiling in benign and
malignant neurofibromatosis type 1-associated nerve sheath tumors:
Evidences of PTEN pathway alterations in early NF1 tumorigenesis.
BMC Genomics. 14:4732013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Camps C, Saini HK, Mole DR, Choudhry H,
Reczko M, Guerra-Assunção JA, Tian YM, Buffa FM, Harris AL,
Hatzigeorgiou AG, et al: Integrated analysis of microRNA and mRNA
expression and association with HIF binding reveals the complexity
of microRNA expression regulation under hypoxia. Mol Cancer.
13:282014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Semenza GL: Hypoxia-inducible factor 1:
Master regulator of O2 homeostasis. Curr Opin Genet Dev.
8:588–594. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ben-Yosef Y, Miller A, Shapiro S and Lahat
N: Hypoxia of endothelial cells leads to MMP-2-dependent survival
and death. Am J Physiol Cell Physiol. 289:C1321–C1331. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kitano H: Cancer as a robust system:
Implications for anticancer therapy. Nat Rev Cancer. 4:227–235.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Melillo G and Semenza GL: Meeting report:
Exploiting the tumor microenvironment for therapeutics. Cancer Res.
66:4558–4560. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nallamshetty S, Chan SY and Loscalzo J:
Hypoxia: A master regulator of microRNA biogenesis and activity.
Free Radic Biol Med. 64:20–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gee HE, Ivan C, Calin GA and Ivan M:
HypoxamiRs and cancer: From biology to targeted therapy. Antioxid
Redox Signal. 21:1220–1238. 2014.10.1089/ars.2013.5639. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen KC, Liao YC, Wang JY, Lin YC, Chen CH
and Juo SH: Oxidized low-density lipoprotein is a common risk
factor for cardiovascular diseases and gastroenterological cancers
via epigenomical regulation of microRNA-210. Oncotarget.
6:24105–24118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Y, Qu A, Liu J, Wang R, Liu Y, Li G,
Duan W, Fang Q, Jiang X, Wang L, et al: Serum miR-210 contributes
to tumor detection, stage prediction and dynamic surveillance in
patients with bladder cancer. PLoS One. 10:e01351682015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Humeau M, Vignolle-Vidoni A, Sicard F,
Martins F, Bournet B, Buscail L, Torrisani J and Cordelier P:
Salivary MicroRNA in pancreatic cancer patients. PLoS One.
10:e01309962015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dang K and Myers KA: The role of
hypoxia-induced miR-210 in cancer progression. Int J Mol Sci.
16:6353–6372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang X, Ding L, Bennewith KL, Tong RT,
Welford SM, Ang KK, Story M, Le QT and Giaccia AJ:
Hypoxia-inducible mir-210 regulates normoxic gene expression
involved in tumor initiation. Mol Cell. 35:856–867. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang X, Le QT and Giaccia AJ: MiR-210 -
micromanager of the hypoxia pathway. Trends Mol Med. 16:230–237.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ying Q, Liang L, Guo W, Zha R, Tian Q,
Huang S, Yao J, Ding J, Bao M, Ge C, et al: Hypoxia-inducible
microRNA-210 augments the metastatic potential of tumor cells by
targeting vacuole membrane protein 1 in hepatocellular carcinoma.
Hepatology. 54:2064–2075. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hwang HW, Baxter LL, Loftus SK, Cronin JC,
Trivedi NS, Borate B and Pavan WJ: Distinct microRNA expression
signatures are associated with melanoma subtypes and are regulated
by HIF1A. Pigment Cell Melanoma Res. 27:777–787. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fasanaro P, D'Alessandra Y, Di Stefano V,
Melchionna R, Romani S, Pompilio G, Capogrossi MC and Martelli F:
MicroRNA-210 modulates endothelial cell response to hypoxia and
inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol
Chem. 283:15878–15883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miao H and Wang B: EphA receptor signaling
- complexity and emerging themes. Semin Cell Dev Biol. 23:16–25.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Larson J, Schomberg S, Schroeder W and
Carpenter TC: Endothelial EphA receptor stimulation increases lung
vascular permeability. Am J Physiol Lung Cell Mol Physiol.
295:L431–L439. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Genander M, Halford MM, Xu NJ, Eriksson M,
Yu Z, Qiu Z, Martling A, Greicius G, Thakar S, Catchpole T, et al:
Dissociation of EphB2 signaling pathways mediating progenitor cell
proliferation and tumor suppression. Cell. 139:679–692. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uchiyama S, Saeki N and Ogawa K: Aberrant
EphB/ephrin-B expression in experimental gastric lesions and tumor
cells. World J Gastroenterol. 21:453–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Liu Z, Liu B, Liu G and Wu S:
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve
sheath tumor by TALENs. Oncol Rep. 34:391–398. 2015.PubMed/NCBI
|
|
27
|
Wang Z, Yin B, Wang B, Ma Z, Liu W and Lv
G: MicroRNA-210 promotes proliferation and invasion of peripheral
nerve sheath tumor cells targeting EFNA3. Oncol Res. 21:145–154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mao L, Zhou Q, Zhou S, Wilbur RR and Li X:
Roles of apolipoprotein E (ApoE) and inducible nitric oxide
synthase (iNOS) in inflammation and apoptosis in preeclampsia
pathogenesis and progression. PLoS One. 8:e581682013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galluzzi L and Kroemer G: Necroptosis: A
specialized pathway of programmed necrosis. Cell. 135:1161–1163.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amaravadi RK and Thompson CB: The roles of
therapy-induced autophagy and necrosis in cancer treatment. Clin
Cancer Res. 13:7271–7279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare
S, Kondo S, Kondo Y, Yu Y, Mills GB, et al: The tumor suppressor
gene ARHI regulates autophagy and tumor dormancy in human ovarian
cancer cells. J Clin Invest. 118:3917–3929. 2008.PubMed/NCBI
|
|
34
|
Du Y, Liu Z, Gu L, Zhou J, Zhu BD, Ji J
and Deng D: Characterization of human gastric carcinoma-related
methylation of 9 miR CpG islands and repression of their
expressions in vitro and in vivo. BMC Cancer. 12:2492012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsuruta T, Kozaki K, Uesugi A, Furuta M,
Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a
tumor suppressor microRNA that is silenced by DNA hypermethylation
in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai
CH, Kao HW, Fang WL, Huang KH, Chan WC, et al: Epigenetic
regulation of miR-34b and miR-129 expression in gastric cancer. Int
J Cancer. 129:2600–2610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W,
Tamboli P, Wood CG and Wu X: Hsa-miR-9 methylation status is
associated with cancer development and metastatic recurrence in
patients with clear cell renal cell carcinoma. Oncogene.
29:5724–5728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hashimoto Y, Akiyama Y, Otsubo T, Shimada
S and Yuasa Y: Involvement of epigenetically silenced microRNA-181c
in gastric carcinogenesis. Carcinogenesis. 31:777–784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L
and Wang Z: Epigenetic silencing of miR-130b in ovarian cancer
promotes the development of multidrug resistance by targeting
colony-stimulating factor 1. Gynecol Oncol. 124:325–334. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gorospe M, Tominaga K, Wu X, Fähling M and
Ivan M: Post-transcriptional control of the hypoxic response by
RNA-binding proteins and microRNAs. Front Mol Neurosci. 4:72011.
View Article : Google Scholar : PubMed/NCBI
|
